Morning Market Movers By: Benzinga via Benzinga June 05, 2014 at 09:40 AM EDT Halozyme Therapeutics (NASDAQ: HALO) climbed 17.57% to $9.50 after the company reported that it will resume PEGPH20 clinical program in ... Read More >> Related Stocks: Abraxas Petro Corp Ciena Corp Halozyme Therapeutic Microvision Superior Drilling Products Inc Verint Systems Inc